Caveolae, Caveolin and control of vascular tone: Nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF) regulation

Journal of Physiology and Pharmacology

Volumn 60, Issue , 2009, Pages 105-109

  Rath, G ^a   Dessy, C ^a   Feron, O ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Caveolae; Caveolin; Connexin; EDHF; Endothelium; Endothelium derived hyperpolarizing factor; Gap junction; Nitric oxide; NO; Transient receptor potential (TRP) channel; TRPC1; TRPV4

Indexed keywords

ARACHIDONIC ACID; CALCIUM; CAVEOLIN; CAVEOLIN 1; CONNEXIN 37; CONNEXIN 40; CONNEXIN 43; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; METHYL BETA CYCLODEXTRIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SMALL CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; SMALL INTERFERING RNA; TRANSIENT RECEPTOR POTENTIAL CHANNEL 1; TRANSIENT RECEPTOR POTENTIAL CHANNEL 4; VANILLOID RECEPTOR 4; BIOLOGICAL FACTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIUM DEPENDENT HYPERPOLARIZATION FACTOR; ENDOTHELIUM-DEPENDENT HYPERPOLARIZATION FACTOR;

ARTICLE; BLOOD PRESSURE; BLOOD VESSEL TONE; CALCIUM SIGNALING; CALCIUM TRANSPORT; CAVEOLA; CELL COMPARTMENTALIZATION; ENDOTHELIAL DYSFUNCTION; GENETIC MODEL; HYDROLYSIS; HYPERPOLARIZATION; IMMUNOHISTOCHEMISTRY; NONHUMAN; VASODILATATION; WESTERN BLOTTING; ANIMAL; HUMAN; METABOLISM; MOUSE; MUSCLE TONE; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

ANIMALS; BIOLOGICAL FACTORS; CAVEOLAE; CAVEOLINS; HUMANS; MICE; MUSCLE TONUS; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; SIGNAL TRANSDUCTION;

EID: 77950484537     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol 2007; 8: 185-194.
2. Schwencke C, Braun-Dullaeus RC, Wunderlich C, Strasser RH. Caveolae and caveolin in transmembrane signaling: Implications for human disease. Cardiovasc Res 2006; 70: 42-49.
3. Cohen AW, Hnasko R, Schubert W, Lisanti MP. Role of caveolae and caveolins in health and disease. Physiol Rev 2004; 84: 1341-1379.
4. Sbaa E, Frerart F, Feron O. The double regulation of endothelial nitric oxide synthase by caveolae and caveolin: a paradox solved through the study of angiogenesis. Trends Cardiovasc Med 2005; 15: 157-162.
5. Frank PG, Hassan GS, Rodriguez-Feo JA, Lisanti MP. Caveolae and caveolin-1: novel potential targets for the treatment of cardiovascular disease. Curr Pharm Des 2007; 13: 1761-1769.
6. Feron O, Balligand JL. Caveolins and the regulation of endothelial nitric oxide synthase in the heart. Cardiovasc Res 2006; 69: 788-797.
7. Feron O, Belhassen L, Kobzik L, Smith TW, Kelly RA, Michel T. Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem 1996; 271: 22810-22814.
8. Garcia-Cardena G, Martasek P, Masters BS, et al. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo. J Biol Chem 1997; 272: 25437-25440.
9. Feron O, Saldana F, Michel JB, Michel T. The endothelial nitric-oxide synthase-caveolin regulatory cycle. J Biol Chem 1998; 273: 3125-3128.
10. Sbaa E, Dewever J, Martinive P, et al. Caveolin plays a central role in endothelial progenitor cell mobilization and homing in SDF-1-driven postischemic vasculogenesis. Circ Res 2006; 98: 1219-1227.
11. Feron O, Dessy C, Moniotte S, Desager JP, Balligand JL. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest 1999; 103: 897-905.
12. Feron O, Dessy C, Desager JP, Balligand JL. Hydroxymethylglutaryl- coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001; 103: 113-118.
13. Brouet A, Sonveaux P, Dessy C, Moniotte S, Balligand JL, Feron O. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res 2001; 89: 866-873.
14. Brouet A, Dewever J, Martinive P, et al. Antitumor effects of in vivo caveolin gene delivery are associated with the inhibition of the proangiogenic and vasodilatory effects of nitric oxide. FASEB J 2005; 19: 602-604.
15. Gratton JP, Lin MI, Yu J, et al. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell 2003; 4: 31-39.
16. Drab M, Verkade P, Elger M, et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001; 293: 2449-2452.
17. Razani B, Engelman JA, Wang XB, et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001; 276: 38121- 38138.
18. Yu J, Bergaya S, Murata T, et al. Direct evidence for the role of caveolin-1 and caveolae in mechanotransduction and remodeling of blood vessels. J Clin Invest 2006; 116: 1284- 1291.
19. Murata T, Lin MI, Huang Y, et al. Reexpression of caveolin- 1 in endothelium rescues the vascular, cardiac, and pulmonary defects in global caveolin-1 knockout mice. J Exp Med 2007; 204: 2373-2382.
20. Desjardins F, Lobysheva I, Pelat M, et al. Control of blood pressure variability in caveolin-1-deficient mice: role of nitric oxide identified in vivo through spectral analysis. Cardiovasc Res 2008; 79: 527-536.
21. Pelat M, Dessy C, Massion P, Desager JP, Feron O, Balligand JL. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo. Circulation 2003; 107: 2480-2486.
22. Sega R, Corrao G, Bombelli M, et al. Blood pressure variability and organ damage in a general population: results from the PAMELA study (Pressioni Arteriose Monitorate E Loro Associazioni). Hypertension 2002; 39: 710-714.
23. Saliez J, Bouzin C, Rath G, et al. Role of caveolar compartmentation in endothelium-derived hyperpolarizing factor-mediated relaxation: Ca2+ signals and gap junction function are regulated by caveolin in endothelial cells. Circulation 2008; 117: 1065-1074.
24. Jin J, Caldwell RB, Li-Masters T, RW Caldwell. Homocysteine induces endothelial dysfunction via inhibition of arginine transport. J Physiol Pharmacol 2007; 58: 191-206.
25. Marrelli SP. Mechanisms of endothelial P2Y(1)- and P2Y(2)-mediated vasodilatation involve differential [Ca2+]i responses. Am J Physiol Heart Circ Physiol 2001; 281: H1759-H1766.
26. Isshiki M, Anderson RG. Function of caveolae in Ca2+ entry and Ca2+-dependent signal transduction. Traffic 2003; 4: 717-723.
27. Parekh AB, Putney JW, Jr. Store-operated calcium channels. Physiol Rev 2005; 85: 757-810.
28. Lockwich TP, Liu X, Singh BB, Jadlowiec J, Weiland S, Ambudkar IS. Assembly of Trp1 in a signaling complex associated with caveolin-scaffolding lipid raft domains. J Biol Chem 2000; 275: 11934-11942.
29. Singh BB, Liu X, Ambudkar IS. Expression of truncated transient receptor potential protein 1alpha (Trp1alpha): evidence that the Trp1 C terminus modulates store-operated Ca2+ entry. J Biol Chem 2000; 275: 36483-36486.
30. Brazer SC, Singh BB, Liu X, Swaim W, Ambudkar IS. Caveolin-1 contributes to assembly of store-operated Ca2+ influx channels by regulating plasma membrane localization of TRPC1. J Biol Chem 2003; 278: 27208-27215.
31. 2+ signaling microdomains:platforms for the assembly and regulation of TRPC channels. Trends Pharmacol Sci 2006; 27: 25-32.
32. Nilius B, Droogmans G, Wondergem R. Transient receptor potential channels in endothelium: solving the calcium entry puzzle? Endothelium 2003; 10: 5-15.
33. Kohler R, Heyken WT, Heinau P, et al. Evidence for a functional role of endothelial transient receptor potential V4 in shear stress-induced vasodilatation. Arterioscler Thromb Vasc Biol 2006; 26: 1495-1502.
34. Liedtke W, Choe Y, Marti-Renom MA, et al. Vanilloid receptor-related osmotically activated channel (VROAC), a candidate vertebrate osmoreceptor. Cell 2000; 103: 525-535.
35. Hartmannsgruber V, Heyken WT, Kacik M, et al. Arterial response to shear stress critically depends on endothelial TRPV4 expression. PLoS ONE 2007; 2: e827.
36. Watanabe H, Vriens J, Suh SH, Benham CD, Droogmans G, Nilius B. Heat-evoked activation of TRPV4 channels in a HEK293 cell expression system and in native mouse aorta endothelial cells. J Biol Chem 2002; 277: 47044- 47051.
37. Suzuki M, Mizuno A, Kodaira K, Imai M. Impaired pressure sensation in mice lacking TRPV4. J Biol Chem 2003; 278: 22664-22668.
38. Watanabe H, Vriens J, Prenen J, Droogmans G, Voets T, Nilius B. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature 2003; 424: 434-438.
39. Vriens J, Owsianik G, Fisslthaler B, et al. Modulation of the Ca2 permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium. Circ Res 2005; 97: 908-915.
40. Graziani A, Bricko V, Carmignani M, Graier WF, Groschner K. Cholesterol- and caveolin-rich membrane domains are essential for phospholipase A2-dependent EDHF formation. Cardiovasc Res 2004; 64: 234-242.
41. Absi M, Burnham MP, Weston AH, Harno E, Rogers M, Edwards G. Effects of methyl beta-cyclodextrin on EDHF responses in pig and rat arteries; association between SK(Ca) channels and caveolin-rich domains. Br J Pharmacol 2007; 151: 332-340.
42. Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, Weston AH. EDHF: bringing the concepts together. Trends Pharmacol Sci 2002; 23: 374-380.
43. Sandow SL, Tare M, Coleman HA, Hill CE, Parkington HC. Involvement of myoendothelial gap junctions in the actions of endothelium-derived hyperpolarizing factor. Circ Res 2002; 90: 1108-1113.
44. Sandow SL. Factors, fiction and endothelium-derived hyperpolarizing factor. Clin Exp Pharmacol Physiol 2004; 31: 563-570.
45. Sokoya EM, Burns AR, Setiawan CT, Coleman HA, Parkington HC, Tare M. Evidence for the involvement of myoendothelial gap junctions in EDHF-mediated relaxation in the rat middle cerebral artery. Am J Physiol Heart Circ Physiol 2006; 291: H385-H393.
46. Yeager M, Unger VM, Falk MM. Synthesis, assembly and structure of gap junction intercellular channels. Curr Opin Struct Biol 1998; 8: 517-524.
47. Figueroa XF, Isakson BE, Duling BR. Connexins: gaps in our knowledge of vascular function. Physiology (Bethesda) 2004; 19: 277-284.
48. Li X, Simard JM. Increase in Cx45 gap junction channels in cerebral smooth muscle cells from SHR. Hypertension 2002; 40: 940-946.
49. Hill CE, Rummery N, Hickey H, Sandow SL. Heterogeneity in the distribution of vascular gap junctions and connexins: implications for function. Clin Exp Pharmacol Physiol 2002; 29: 620-625.
50. de Wit C, Hoepfl B, Wolfle SE. Endothelial mediators and communication through vascular gap junctions. Biol Chem 2006; 387: 3-9.
51. Liao Y, Day KH, Damon DN, Duling BR. Endothelial cellspecific knockout of connexin 43 causes hypotension and bradycardia in mice. Proc Natl Acad Sci USA 2001; 98: 9989-9994.
52. Simon AM, McWhorter AR. Decreased intercellular dyetransfer and downregulation of non-ablated connexins in aortic endothelium deficient in connexin37 or connexin40. J Cell Sci 2003; 116: 2223-2236.
53. Nusrat A, Parkos CA, Verkade P, et al. Tight junctions are membrane microdomains. J Cell Sci 2000; 113(Pt 10): 1771- 1781.
54. Schubert AL, Schubert W, Spray DC, Lisanti MP. Connexin family members target to lipid raft domains and interact with caveolin-1. Biochemistry 2002; 41: 5754-5764.
55. Joshi MS, Mineo C, Shaul PW, Bauer JA. Biochemical consequences of the NOS3 Glu298Asp variation in human endothelium: altered caveolar localization and impaired response to shear. FASEB J 2007; 21: 2655-2663.